Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its ...

VistaGen Therapeutics, Inc. (NASDAQ ... We encourage you to review the release and our 10-Q, which can be found in the Investors section of our website. We will make forward-looking statements ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Matthew Kaplan; Analyst; Ladenburg Thalmann & Co. Inc Mayank Mamtani; Analyst; B. Riley Securities ...

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

The biopharmaceutical company posted revenue of $83.9 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $80.3 million. TG Therapeutics expects full-year ...

TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

P4L AI users benefit from in-platform diamonds, which they will soon be able to convert into $P4L tokens. This planned ...

On Tuesday, TD Cowen initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX), assigning a Buy rating with a price target of $50.00. The firm's coverage is based on the potential of TG ...

Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He ...